Article
Novel polymeric fluoropyrimidine CF10 demonstrates superior therapeutic index and survival advantage in patient-derived models of 5-fluorouracil-refractory colorectal cancer
2026-04-08
Abstract excerpt
<h4>Background</h4> Fluoropyrimidines, specifically 5-fluorouracil (5-FU), remain the cornerstone of colorectal cancer (CRC) therapy. However, intrinsic and acquired resistance, alongside dose-limiting systemic toxicities, often result in treatment failure and disease relapse. There is a pressing clinical need for next-generation fluoropyrimidines that can retain the antitumor activity in 5-FU-refractory CRC mode...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 8284653b-0cd2-5813-b481-dac5bfc45472
- DOI
- 10.64898/2026.04.05.716582
